Down-regulated FST Expression is Involved in the Poor Prognosis of Triple-negative Breast Cancer

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2021 May 18

PMID 34001106

Citations 4

Authors

Sainan Liu

Bin Liu

Qian Zhao

Jikang Shi

Yulu Gu

Yanbo Guo

Yong Li

Yunkai Liu

Yi Cheng

Yichun Qiao

Yawen Liu

Affiliations

Soon will be listed here.

Abstract

Background: Triple-negative breast cancer (TNBC) is more commonly associated with young patients, featuring high histological grade, visceral metastasis, and distant recurrence. Follistatin (FST) is a secreted extracellular regulatory protein that antagonizes TGF-β superfamily such as activin and TGF-β related superfamily such as bone morphogenetic protein (BMP). The implication of FST in the proliferation, angiogenesis, and metastasis of solid tumors documents good or poor outcome of patients with BC. However, the role of FST in TNBC remains unclear.

Methods: Data of 935 patients with breast cancer (BC) were extracted from TCGA. Case-control study, Kaplan-Meier, uni-multivariate COX, and ROC curve were utilized to investigate the relationship between FST expression and the clinical characteristics and prognosis of BC. Functional studies were used to analyze the effect of FST expression on proliferation, apoptosis, migration, and invasion of TNBC cell lines. Bioinformatic methods such as volcanoplot, GO annd KEGG enrichment, and protein-protein interactions (PPI) analyses were conducted to further confirm the different roles of FST in the apoptotic pathways among mesenchymal and mesenchymal stem-like cells of TNBC.

Results: Data from TCGA showed that low FST expression correlated with poor prognosis (for univariate analysis, HR = 0.47, 95% CI: 0.27-0.82, p = 0.008; for multivariate analysis, HR = 0.40, 95% CI: 0.21-0.75, p = 0.004). Low FST expression provided high predicted value of poor prognosis in TNBC amongst BCs. FST knockdown promoted the proliferation, migration and invasion of BT549 and HS578T cell lines. FST inhibited the apoptosis of mesenchymal cells by targeting BMP7.

Conclusions: Low FST expression is associated with poor prognosis of patients with TNBC. FST expressions exhibit the anisotropic roles of apoptosis between mesenchymal and mesenchymal stem-like cells but promote the proliferation, migration, invasion in both of two subtypes of TNBC in vitro. FST may be a subtype-heterogeneous biomarker for monitoring the progress of TNBC.

Citing Articles

Transcriptome Analysis Reveals the Molecular Mechanism of PLIN1 in Goose Hierarchical and Pre-Hierarchical Follicle Granulosa Cells.

He H, Lin Y, Zhang X, Xie H, Wang Z, Hu S Animals (Basel). 2025; 15(2).

PMID: 39858284 PMC: 11761271. DOI: 10.3390/ani15020284.

The Reign of Follistatin in Tumors and Their Microenvironment: Implications for Drug Resistance.

Sosa J, Oyelakin A, Sinha S Biology (Basel). 2024; 13(2).

PMID: 38392348 PMC: 10887188. DOI: 10.3390/biology13020130.

Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential.

McHenry P, Prosperi J Int J Mol Sci. 2023; 24(3).

PMID: 36768435 PMC: 9916912. DOI: 10.3390/ijms24032100.

Integrated Machine Learning and Single-Sample Gene Set Enrichment Analysis Identifies a TGF-Beta Signaling Pathway Derived Score in Headneck Squamous Cell Carcinoma.

Wu S, Lv X, Li Y, Gao X, Ma Z, Fu X J Oncol. 2022; 2022:3140263.

PMID: 36090900 PMC: 9458367. DOI: 10.1155/2022/3140263.

Zeng D, Wang X, Zhang S, Zheng A, Huang Q, Cao L Front Surg. 2022; 9:903271.

PMID: 36061051 PMC: 9437919. DOI: 10.3389/fsurg.2022.903271.

References

Zabkiewicz C, Resaul J, Hargest R, Jiang W, Ye L . Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival. Cancer Genomics Proteomics. 2017; 14(4):241-251. PMC: 5572302. DOI: 10.21873/cgp.20035. View

Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H . Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal. 2009; 7:15. PMC: 2713245. DOI: 10.1186/1478-811X-7-15. View

Neophytou C, Boutsikos P, Papageorgis P . Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis. Front Oncol. 2018; 8:31. PMC: 5827095. DOI: 10.3389/fonc.2018.00031. View

Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F . Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012; 7(10):e46536. PMC: 3477108. DOI: 10.1371/journal.pone.0046536. View

Sengupta D, Bhargava D, Dixit A, Sahoo B, Biswas S, Biswas G . ERRβ signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells. Br J Cancer. 2014; 110(8):2144-58. PMC: 3992508. DOI: 10.1038/bjc.2014.53. View

Liu J, Zeng S, Wang Y, Yu J, Ouyang Q, Hu L . Essentiality of CTNNB1 in Malignant Transformation of Human Embryonic Stem Cells under Long-Term Suboptimal Conditions. Stem Cells Int. 2020; 2020:5823676. PMC: 7532415. DOI: 10.1155/2020/5823676. View

Wallner C, Drysch M, Becerikli M, Jaurich H, Wagner J, Dittfeld S . Interaction with the GDF8/11 pathway reveals treatment options for adenocarcinoma of the breast. Breast. 2017; 37:134-141. DOI: 10.1016/j.breast.2017.11.010. View

Cash J, Angerman E, Kattamuri C, Nolan K, Zhao H, Sidis Y . Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding. J Biol Chem. 2011; 287(2):1043-53. PMC: 3256893. DOI: 10.1074/jbc.M111.270801. View

Couto H, Dela Cruz C, Buzelin M, Toppa N, Wainstein A, Reis F . Follistatin Expression in Human Invasive Breast Tumors: Pathologic and Clinical Associations. Appl Immunohistochem Mol Morphol. 2016; 26(2):108-112. DOI: 10.1097/PAI.0000000000000385. View

10.

Ohta N, Ishiguro S, Kawabata A, Uppalapati D, Pyle M, Troyer D . Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes. PLoS One. 2015; 10(5):e0123756. PMC: 4420498. DOI: 10.1371/journal.pone.0123756. View

11.

Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, Vasan N . The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34(3):427-438.e6. PMC: 6327853. DOI: 10.1016/j.ccell.2018.08.008. View

12.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

13.

Sticker D, Lechner S, Jungreuthmayer C, Zanghellini J, Ertl P . Microfluidic Migration and Wound Healing Assay Based on Mechanically Induced Injuries of Defined and Highly Reproducible Areas. Anal Chem. 2017; 89(4):2326-2333. DOI: 10.1021/acs.analchem.6b03886. View

14.

Gong Y, Ji P, Yang Y, Xie S, Yu T, Xiao Y . Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metab. 2020; 33(1):51-64.e9. DOI: 10.1016/j.cmet.2020.10.012. View

15.

Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X . Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019; 35(3):428-440.e5. DOI: 10.1016/j.ccell.2019.02.001. View

16.

Reis F, Luisi S, Carneiro M, Cobellis L, Federico M, Camargos A . Activin, inhibin and the human breast. Mol Cell Endocrinol. 2004; 225(1-2):77-82. DOI: 10.1016/j.mce.2004.02.016. View

17.

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

18.

Seachrist D, Sizemore S, Johnson E, Abdul-Karim F, Bonk K, Keri R . Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. Breast Cancer Res. 2017; 19(1):66. PMC: 5460489. DOI: 10.1186/s13058-017-0857-y. View

19.

Mock K, Preca B, Brummer T, Brabletz S, Stemmler M, Brabletz T . The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors. Oncotarget. 2015; 6(16):14399-412. PMC: 4546475. DOI: 10.18632/oncotarget.3882. View

20.

Welt C, Sidis Y, Keutmann H, Schneyer A . Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood). 2002; 227(9):724-52. DOI: 10.1177/153537020222700905. View